Home > Insider Trading > Filing (0001209191-16-156690)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175505	Five Prime Therapeutics Inc	FPRX	Pharmaceutical Preparations (2834)	260038620

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1475714	T Lewis Williams	Two Corporate Drive South San Francisco CA 94080	President, Ceo And Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-12-23	155	$4.56	434,047	No	4	M	Direct
Common Stock	Acquisiton	2016-12-23	19	$6.89	434,066	No	4	M	Direct
Common Stock	Acquisiton	2016-12-23	10	$8.49	434,076	No	4	M	Direct
Common Stock	Acquisiton	2016-12-23	29,816	$5.54	463,892	No	4	M	Direct
Common Stock	Disposition	2016-12-23	29,700	$50.49	434,192	No	4	S	Direct
Common Stock	Disposition	2016-12-23	300	$51.02	433,892	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-12-23	155	$0.00	155	$4.56
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-12-23	19	$0.00	19	$6.89
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-12-23	10	$0.00	10	$8.49
Common Stock	Employee Stock Option (right to buy)	Disposition	2016-12-23	29,816	$0.00	29,816	$5.54

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
91,217	2019-04-15	No	4	M	Direct
14,438	2020-07-28	No	4	M	Direct
16,349	2021-10-19	No	4	M	Direct
31,159	2022-07-15	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.04, inclusive.
This option is fully vested and immediately exercisable.